{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:17:13Z","timestamp":1789143433460,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.abd.2022.05.004","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T09:30:23Z","timestamp":1676626223000},"page":"302-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome \u2013 A literature review"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-1039","authenticated-orcid":false,"given":"Anna Danielly Almeida do","family":"Nascimento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2441","authenticated-orcid":false,"given":"D\u00e9bora Maria","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-2471","authenticated-orcid":false,"given":"Aurora Karla de Lacerda","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2022.05.004_bib0005","first-page":"13","article-title":"Terapia combinada com quimioter\u00e1picos e seus efeitos cardiot\u00f3xicos no tratamento de pacientes oncol\u00f3gicos","volume":"2","author":"Anjos","year":"2021","journal-title":"Rev Mult Saude"},{"key":"10.1016\/j.abd.2022.05.004_bib0010","series-title":"[disserta\u00e7\u00e3o - Mestrado em Sa\u00fade P\u00fablica]","article-title":"Tratamento e disposi\u00e7\u00e3o final de res\u00edduos de medicamentos quimioter\u00e1picos e de rejeitos radioter\u00e1picos: estudo comparativo entre a legisla\u00e7\u00e3o internacional e a brasileira","author":"Costa","year":"2010"},{"key":"10.1016\/j.abd.2022.05.004_bib0015","first-page":"157","article-title":"Rea\u00e7\u00f5es adversas na cavidade oral em decorr\u00eancia do uso de medicamentos","volume":"36","author":"Pires","year":"2017","journal-title":"Saluvista"},{"key":"10.1016\/j.abd.2022.05.004_bib0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel","volume":"95","author":"Cury-Martins","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2022.05.004_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.2008.03159.x","article-title":"Candidate mechanisms for capecitabine related hand-foot syndrome","volume":"66","author":"Milano","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.abd.2022.05.004_bib0030","first-page":"24","article-title":"Adverse reaction induced by capecitabine: the importance of pharmacovigilance","volume":"4","author":"Martins","year":"2013","journal-title":"Rev Bras Farm Hosp S Saude"},{"key":"10.1016\/j.abd.2022.05.004_bib0035","series-title":"Medical Genetics Summaries [Internet]","article-title":"Capecitabine therapy and DPYD genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.abd.2022.05.004_bib0040","series-title":"[disserta\u00e7\u00e3o - Mestrado em Farmacologia] . [Campinas]: Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas","article-title":"Estudo de biodisponibilidade comparativa da Capecitabina em participantes sadios do sexo masculino ap\u00f3s alimenta\u00e7\u00e3o","author":"Matos","year":"2018"},{"key":"10.1016\/j.abd.2022.05.004_bib0045","unstructured":"S.C. Sweetman, Martindale: the complete drug reference, 36. ed., 2009, Chicago:Pharmaceutical Press. 4142p."},{"key":"10.1016\/j.abd.2022.05.004_bib0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1590\/S0365-05962010000400003","article-title":"Adverse mucocutaneous reactions to chemotherapeutic agents: part I","volume":"85","author":"Sanches Junior","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2022.05.004_bib0055","unstructured":"National Cancer Institute (NCI) [Internet]. Division of cancer treatment and diagnosis. Commom toxicity criteria (Computer Program). Version 5.0. NCI; 2017. [cited 2022 Aug 10]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1016\/j.abd.2022.05.004_bib0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1590\/S0365-05962010000500002","article-title":"Adverse mucocutaneous reactions related to chemotherapeutic agents \u2013 Part II","volume":"85","author":"Criado","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2022.05.004_bib0065","first-page":"36","article-title":"Hiperpigmenta\u00e7\u00e3o da mucosa bucal causada pelo uso prolongado de f\u00e1rmaco antimal\u00e1rico","volume":"44","author":"Silveira","year":"2003","journal-title":"R Fac Odontol"},{"key":"10.1016\/j.abd.2022.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33448\/rsd-v10i5.14528","article-title":"Hyperpigmentation in the oral mucosa of patients using chloroquine and hydroxychloroquine: a literature review","volume":"10","author":"Holanda","year":"2021","journal-title":"Res Soc Develop"},{"key":"10.1016\/j.abd.2022.05.004_bib0075","article-title":"Mandibular osteonecrosis and the use of bisphosphonates in a cancer patient: case report","volume":"11","author":"Pereira","year":"2022","journal-title":"Res Soc Develop"},{"key":"10.1016\/j.abd.2022.05.004_bib0080","unstructured":"who.int [Internet] World Health Organization (WHO), The Uppsala Monitoring Centre. The Importance of Pharmacovigilance, Safety Monitoring of medicinal products, 2002, 48. [cited 2022 Aug 10]. Available from: https:\/\/www.who.int\/publications\/i\/item\/10665-42493"},{"key":"10.1016\/j.abd.2022.05.004_bib0085","series-title":"Terap\u00eautica Oncol\u00f3gica para Enfermeiros e Farmac\u00eauticos","author":"Bonassa","year":"2012"},{"key":"10.1016\/j.abd.2022.05.004_bib0090","first-page":"171","article-title":"Capecitabina: un quimioter\u00e1pico oral en la lucha contra el c\u00e2ncer de mama y colorrectal metast\u00e1sico","volume":"27","author":"Rodriguez","year":"2003","journal-title":"Farm Hosp"},{"key":"10.1016\/j.abd.2022.05.004_bib0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0019-5154.39747","article-title":"Hand-foot syndrome due to capecitabine","volume":"53","author":"Surjushe","year":"2008","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.abd.2022.05.004_bib0100","series-title":"Fortaleza. [Disserta\u00e7\u00e3o - Mestrado em Ci\u00eancia] \u2013 Funda\u00e7\u00e3o Ant\u00f4nio Prudente","article-title":"Estudo prospectivo da incid\u00eancia, das caracter\u00edsticas cl\u00ednico-patol\u00f3gicas e da hiperalgesia na s\u00edndrome m\u00e3o-p\u00e9 induzida por capecitabina","author":"Rocha Filho","year":"2010"},{"key":"10.1016\/j.abd.2022.05.004_bib0105","doi-asserted-by":"crossref","first-page":"01","DOI":"10.5380\/ce.v22i1.45824","article-title":"S\u00edndrome m\u00e3o-p\u00e9 induzida pela Capecitabina: Relato de caso","volume":"22","author":"Bispo J\u00fanior","year":"2017","journal-title":"Cogitare Enfermagem"},{"key":"10.1016\/j.abd.2022.05.004_bib0110","first-page":"e","article-title":"S\u00edndrome M\u00e3o-P\u00e9 Induzida por Quimioterapia: Abordagem Cl\u00ednica e Epidemiol\u00f3gica de Pacientes com C\u00e2ncer","volume":"65","author":"Costa","year":"2019","journal-title":"Rev Bras Canc"},{"key":"10.1016\/j.abd.2022.05.004_bib0115","unstructured":"Xeloda: bula para profissionais. [Internet]. Basil\u00e9ia: Roche.[cited 2022 Aug 11]. Avaiable from: https:\/\/dialogoroche.com.br\/content\/dam\/roche-dialogo\/dialogo-brazil-assets\/downloadable-assets\/produtos\/bulas\/xeloda\/Xeloda_Bula_Profissional.pdf"},{"key":"10.1016\/j.abd.2022.05.004_bib0120","first-page":"82","article-title":"Unilateral Hand-Foot Syndrome: Does It Take Sides? Case Report and Literature Review","volume":"11","author":"Cruz","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.abd.2022.05.004_bib0125","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S0034-71672012000200026","article-title":"S\u00edndrome m\u00e3o-p\u00e9 induzida por quimioterapia: relato de um caso","volume":"65","author":"Sim\u00e3o","year":"2012","journal-title":"Rev Bras Enferm"},{"key":"10.1016\/j.abd.2022.05.004_bib0130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000327767","article-title":"Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment","volume":"4","author":"Farr","year":"2011","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.abd.2022.05.004_bib0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mjafi.2012.01.009","article-title":"Capecitabine induced hand-foot syndrome: report of two cases","volume":"69","author":"Sanghi","year":"2013","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.abd.2022.05.004_bib0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2022.05.004_bib0145","first-page":"101","article-title":"Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature","volume":"73","author":"Narasimhan","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.abd.2022.05.004_bib0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/15569520802355774","article-title":"Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?","volume":"27","author":"Saif","year":"2008","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.abd.2022.05.004_bib0155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/0253-7613.70401","article-title":"Um caso incomum de hiperpigmenta\u00e7\u00e3o de capecitabina: a hiperpigmenta\u00e7\u00e3o \u00e9 uma parte da s\u00edndrome m\u00e3o-p\u00e9 ou uma entidade separada?","volume":"42","author":"Vasudevan","year":"2010","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.abd.2022.05.004_bib0160","first-page":"e2397","article-title":"Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity?","volume":"10","author":"Caprez","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.abd.2022.05.004_bib0165","doi-asserted-by":"crossref","first-page":"21047","DOI":"10.3402\/jchimp.v3i3-4.21047","article-title":"Tongue hyperpigmentation associated with chemotherapy","volume":"3","author":"Alfreijat","year":"2013","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.abd.2022.05.004_bib0170","series-title":"Patologia oral e maxillofacial","author":"Neville","year":"2009"},{"key":"10.1016\/j.abd.2022.05.004_bib0175","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMicm1014268","article-title":"Chemotherapy-induced hyperpigmentation of the tongue","volume":"365","author":"Blaya","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:42:57Z","timestamp":1759794177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059623000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0365059623000181"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2022.05.004","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome \u2013 A literature review","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.","name":"copyright","label":"Copyright"}]}}